Drug intelligence / Profile preview

Phytopica

Development stage: Unknown
Lead developer: Phytopharm
Modality: Small Molecules
Administration: Oral

Overview

Phytopica is a branded, plant-derived dietary supplement formulated for veterinary use, specifically in the management of canine atopic dermatitis. It has been evaluated as a glucocorticoid-sparing agent in dogs with atopic dermatitis, showing efficacy in reducing the need for corticosteroids to control symptoms. The mechanism of action is not fully elucidated but is presumed to involve anti-inflammatory and immunomodulatory effects from its phytochemical constituents. Its primary indication is for allergic and inflammatory skin conditions in dogs[1][2].

Brand names: PhytopicaPhytopicaTM
Other names: PhytopicaTM

Beyond the preview

Go deeper on Phytopica.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phytopica.

Explore the full profile